Tags

Type your tag names separated by a space and hit enter

[Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients].
Fortschr Med. 1991 Nov 30; 109(34):707-10.FM

Abstract

The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated.

METHOD

open, non-controlled surveillance study conducted at 744 centers.

PATIENTS

3,076 patients suffering from bronchitis.

MEDICATION

600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose.

END POINTS

evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance.

RESULTS

impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%).

CONCLUSIONS

treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated.

Authors+Show Affiliations

Gerards HH
Inpharzam GmbH, Gräfelfing.
Vits U
No affiliation info available

MeSH

AcetylcysteineAdministration, OralBronchitisDrug Administration ScheduleFemaleHumansMaleMiddle AgedPilot Projects

Pub Type(s)

English Abstract
Journal Article

Language

ger

PubMed ID

1765342

Citation

Gerards, H H., and U Vits. "[Therapy of Bronchitis. Successful Single-dosage Treatment With N-acetylcysteine, Results of an Administration Surveillance Study in 3,076 Patients]." Fortschritte Der Medizin, vol. 109, no. 34, 1991, pp. 707-10.
Gerards HH, Vits U. [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. Fortschr Med. 1991;109(34):707-10.
Gerards, H. H., & Vits, U. (1991). [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. Fortschritte Der Medizin, 109(34), 707-10.
Gerards HH, Vits U. [Therapy of Bronchitis. Successful Single-dosage Treatment With N-acetylcysteine, Results of an Administration Surveillance Study in 3,076 Patients]. Fortschr Med. 1991 Nov 30;109(34):707-10. PubMed PMID: 1765342.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Therapy of bronchitis. Successful single-dosage treatment with N-acetylcysteine, results of an administration surveillance study in 3,076 patients]. AU - Gerards,H H, AU - Vits,U, PY - 1991/11/30/pubmed PY - 1991/11/30/medline PY - 1991/11/30/entrez SP - 707 EP - 10 JF - Fortschritte der Medizin JO - Fortschr Med VL - 109 IS - 34 N2 - UNLABELLED: The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated. METHOD: open, non-controlled surveillance study conducted at 744 centers. PATIENTS: 3,076 patients suffering from bronchitis. MEDICATION: 600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose. END POINTS: evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance. RESULTS: impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%). CONCLUSIONS: treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated. SN - 0015-8178 UR - https://www.unboundmedicine.com/medline/citation/1765342/ L2 - https://medlineplus.gov/acutebronchitis.html DB - PRIME DP - Unbound Medicine ER -